J 2021

Improvement of the Diagnosis of Isoattenuating Pancreatic Carcinomas by Defining Their Characteristics on Contrast Enhanced Computed Tomography and Endosonography with Fine-Needle Aspiration (EUS-FNA)

PSÁR, Robert, Ondřej URBAN, Marie ČERNÁ, Tomáš ROHAN, Martin HILL et. al.

Basic information

Original name

Improvement of the Diagnosis of Isoattenuating Pancreatic Carcinomas by Defining Their Characteristics on Contrast Enhanced Computed Tomography and Endosonography with Fine-Needle Aspiration (EUS-FNA)

Authors

PSÁR, Robert (203 Czech Republic, guarantor), Ondřej URBAN (203 Czech Republic), Marie ČERNÁ (203 Czech Republic), Tomáš ROHAN (203 Czech Republic, belonging to the institution) and Martin HILL (203 Czech Republic)

Edition

Diagnostics, Švýcarsko, MDPI, 2021, 2075-4418

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30224 Radiology, nuclear medicine and medical imaging

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.992

RIV identification code

RIV/00216224:14110/21:00121876

Organization unit

Faculty of Medicine

DOI

UT WoS

000653806900001

Keywords in English

computed tomography; early diagnosis; endoscopic ultrasound-guided fine needle aspiration; isoattenuation; pancreatic carcinoma

Tags

Tags

International impact, Reviewed
Změněno: 23/8/2021 08:28, Mgr. Tereza Miškechová

Abstract

V originále

(1) Background. The aim was to define typical features of isoattenuating pancreatic carcinomas on computed tomography (CT) and endosonography and determine the yield of fine-needle aspiration endosonography (EUS-FNA) in their diagnosis. (2) Methods. One hundred and seventy-three patients with pancreatic carcinomas underwent multiphase contrast-enhanced CT followed by EUS-FNA at the time of diagnosis. Secondary signs on CT, size and location on EUS, and the yield of EUS-FNA in isoattenuating and hypoattenuating pancreatic cancer, were evaluated. (3) Results. Isoattenuating pancreatic carcinomas occurred in 12.1% of patients. Secondary signs of isoattenuating pancreatic carcinomas on CT were present in 95.2% cases and included dilatation of the pancreatic duct and/or the common bile duct (85.7%), interruption of the pancreatic duct (76.2%), abnormal pancreatic contour (33.3%), and atrophy of the distal parenchyma (9.5%) Compared to hypoattenuating pancreatic carcinomas, isoattenuating carcinomas were more often localized in the pancreatic head (100% vs. 59.2%; p < 0.001). In ROC (receiver operating characteristic) analysis, the optimal cut-off value for the size of isoattenuating carcinomas on EUS was <= 25 mm (AUC = 0.898). The sensitivity of EUS-FNA in confirmation of isoattenuating and hypoattenuating pancreatic cancer were 90.5% and 92.8% (p = 0.886). (4) Conclusions. Isoattenuating pancreatic head carcinoma can be revealed by indirect signs on CT and confirmed with high sensitivity by EUS-FNA.